Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors

This study has been completed.
Sponsor:
Information provided by:
Stanford University
ClinicalTrials.gov Identifier:
NCT00186225
First received: September 13, 2005
Last updated: July 23, 2010
Last verified: July 2010

September 13, 2005
July 23, 2010
November 1989
June 2007   (final data collection date for primary outcome measure)
oxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors. [ Time Frame: unknown ] [ Designated as safety issue: Yes ]
Toxicity and efficacy of TBI and cyclophosphamide as preparation for hematopoietic cell transplantation from partially matched and unrelated donors.
Complete list of historical versions of study NCT00186225 on ClinicalTrials.gov Archive Site
  • Overall Survival [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • Event Free Survival [ Time Frame: unknown ] [ Designated as safety issue: No ]
  • - Relapse
  • - Overall Survival
  • - Event Free Survival
Not Provided
Not Provided
 
Stem Cell Transplant From Matched Unrelated or Partially Matched Related Donors
Stem Cell Transplantation From Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY)

To evaluate the use of unrelated donors for hematopoietic cell transplantation in the treatment of hematologic and lymphoid malignancies.

Stem Cell Transplantation from Matched Unrelated or Partially Matched Related Donors Using a Preparatory Regimen Consisting of Fractionated Total Body Irradiation (FTBI) and Cyclophosphamide (CY). To administer high dose radio-chemotherapy followed by stem cell transplantation from a matched unrelated donor or a partially matched related donor.

Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Blood Cancer
  • Blood and Marrow Transplant (BMT)
Procedure: ablative allogeneic hematopoietic cell transplantation
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
250
May 2010
June 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:- acute leukemia

  • chronic leukemia
  • lymphoblastic lymphoma
  • MDS
  • MPS

Exclusion Criteria:- organ dysfunction

- HIV positive

Both
up to 50 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00186225
BMT22, 75268, BMT22
Not Provided
Laura Johnston, Stanford University School of Medicine
Stanford University
Not Provided
Principal Investigator: Laura Johnston Stanford University
Stanford University
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP